St John's wort has little effect in ADHD

29 June 2008

Children and teens with attention-deficit/hyperactivity disorder (ADHD) who were treated with the herb St John's wort did not have any greater improvement in ADHD symptoms compared to those who received placebo, according to a study in the June 11 issue of the Journal of the American Medical Association.

ADHD affects 3% to 12% of children in the USA. Up to 30% of these children do not respond to pharmaceutical medications or have adverse effects such as nausea, insomnia, or weight loss from the medications, according to background information in the article.

"For these reasons, many parents seek complementary or alternative medicine for their children with ADHD. Complementary or alternative medicine treatments used for pediatric ADHD include massage, dietary changes, dietary supplements and herbal treatments. In the USA, the most common herbal treatments used by children with ADHD are St John's wort, Echinacea species, and Ginkgo biloba," the authors write.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight